Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis

Inclusion Criteria: * Histologically proven oligodendroglioma or anaplastic oligoastrocytoma, newly diagnosed, resulting or not from a low grade glioma * Tumor with measurable contrast enhancement (at least 15 mm in diameter) * Surgical procedure limited to a biopsy or partial excision * In the event of partial excision, an early postoperative check-up (\<72 hours) performed at best by MRI, if not by CT, is required. * Time between surgery and inclusion less than or equal to one and a half months (45 days) * Age\> 18 years old; \<70 * Karnofsky index\> 60 * Stable or reduced dose of corticosteroids in the 15 days prior to inclusion * Polynuclear neutrophils\> 1500; platelets\> 100,000 * Bilirubin \<1.25 x UNL; SGOT, SGPT, PAL \<2.5 x UNL * Absence of serious uncontrolled pathology * Patient having received and understood the information and having signed the consent Exclusion Criteria: * Presence of GBM foci within the tumor * Absence of evaluable residue after surgery * Previous chemotherapy or radiotherapy * Unsatisfactory expected monitoring conditions * Pregnant or breastfeeding woman; lack of effective contraception if of childbearing age * History of malignant disease (with the exception of CIS of the cervix and basal cell cancer) * Contraindications related to the examination of the I.R.M.